| |
|
|
|
|
|
 |
| |
|
Ææ½Ãºñ¾îÅ©¸²(Ææ½ÃŬ·Î¹ö) 5g Pencivier Cream
|
Àü¹®ÀǾàǰ | ±Þ¿©
|
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
Àü¹®/ÀÏ¹Ý |
Àü¹®
|
|
Á¦Á¶È¸»ç |
ÁÖ½Äȸ»çÁ¦´º¿ø»çÀ̾ð½º
|
ÆÇ¸Åȸ»ç |
ÁÖ½Äȸ»çÁ¦´º¿ø»çÀ̾ð½º
|
Çã°¡Á¤º¸ |
Á¤»ó
(2019.12.30)
|
BIT ¾àÈ¿ºÐ·ù |
¿Ü¿ë Ç×¹ÙÀÌ·¯½ºÁ¦ (Antivirals : Skin & Mucous Membrane)
|
º¹ÁöºÎºÐ·ù |
269[±âŸÀÇ ¿ÜÇÇ¿ë¾à ] |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå |
671706271 \1,908 ¿ø/5g/°³(2021.03.05)(ÇöÀç¾à°¡)\1,908 ¿ø/5g/°³(2020.11.01) (º¯°æÀü¾à°¡)
|
|
|
ATCÄÚµå |
Penciclovir / D06BB06 |
NDCÄÚµå |
[Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]
[Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]
[NDC Number Search _ NDCÄÚµå·Î °Ë»ö]
|
¼ººÐ / ÇÔ·® |
[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]

|
÷°¡Á¦ |
¹é»ö¹Ù¼¿¸°,
¼¼Å丶ũ·Î°ñ1000,
¼¼Å佺Å׾Ƹ±¾ËÄÚ¿Ã,
¼Ò¸£ºñź¼¼½ºÄû¿Ã·¹¿¡ÀÌÆ®,
À¯µ¿ÆÄ¶óÇÉ,
Á¤Á¦¼ö,
ÅäÄÚÆä·Ñ¾Æ¼¼Å×ÀÌÆ®,
ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿,
ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ,
ÇÁ·ÎÇÊ·»±Û¸®ÄÝ
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Penciclovir¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Penciclovir has in vitro activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form. The monophosphate form of the drug is then converted to penciclovir triphosphate by cellular kinases. The intracellular triphosphate of penciclovir is retained in vitro inside HSV-infected cells for 10-20 hours, compared with 0.7-1 hour for acyclovir. in vitro studies show that penciclovir triphosphate selectively inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. Inhibition of DNA synthesis of virus-infected cells inhibits viral replication. In cells not infected with HSV, DNA synthesis is unaltered. Resistant mutants of HSV can occur from qualitative changes in viral thymidine kinase or DNA polymerase. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase are also resistant to penciclovir.
|
| Pharmacology |
Penciclovir¿¡ ´ëÇÑ Pharmacology Á¤º¸ Penciclovir is the active metabolite of the oral product famciclovir. The more favorable results observed with topical penciclovir versus topical acyclovir for the treatment of herpes labialis may be due to the longer intracellular half-life of penciclovir in HSV-infected cells.
|
| Metabolism |
Penciclovir¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Aldehyde oxidase
|
| Protein Binding |
Penciclovir¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Less than 20%.
|
| Half-life |
Penciclovir¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 2 hours
|
| Absorption |
Penciclovir¿¡ ´ëÇÑ Absorption Á¤º¸ Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n= 12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily.
|
| Pharmacokinetics |
PenciclovirÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£:
Herpes zoster °¨¿° : famciclovir·Î Ä¡·á¹Þ´Â ȯÀÚÀÇ °æ¿ì , median times to full °¡ÇÇ »ý¼º, ¼öÆ÷ »ç¶óÁü, ±Ë¾ç ¼Ò½ÇÀ» °ÅÃÄ °¡ÇǼҽDZîÁö´Â °¢°¢ 6ÀÏ, 5ÀÏ, 7ÀÏ, 19ÀÏ ¼Ò¿äµÊ. ±Þ¼º ÅëÁõÀÌ °¨¼ÒµÇ´Âµ¥ °É¸®´Â Æò±Õ½Ã°£Àº 21ÀÏÀ̾úÀ½.
- ÃÖ°íÈ¿°ú ¹ßÇö½Ã°£: iv – 60ºÐ
- Èí¼ö:
1) °æ±¸Á¦ – ³·À½
2)±¹¼Ò¿Ü¿ëÁ¦ – ÃøÁ¤µÇÁö ¾ÊÀ» Á¤µµ·Î ³·À½.
- ´Ü¹é°áÇÕ: 20% ÀÌÇÏ
- ´ë»ç:
1)Intracellular¼¼Æ÷³», ±¤¹üÀ§ ´ë»ç
2)Penciclovir´Â ¹ÙÀÌ·¯½º thymidine kinase¿¡ ÀÇÇØ ¼±ÅÃÀûÀ¸·Î monophosphate ÇüÅ·ΠÀλêÈµÈ ÈÄ, ¼¼Æ÷³» È¿¼Ò¿¡ ÀÇÇØ Ȱ¼ºÇüÀÎ triphosphate·Î ÀüȯµÈ´Ù.
- ¼Ò½Ç:
1)À¯ÁóºÐºñ
-¼öÀ¯: ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀ½.
2)½ÅÀå¹è¼³
-½Å¹è¼³: 28.1 L/hr (Á¤¸Æ Åõ¿©½Ã)
-¾à 70%°¡ ¹Ìº¯È¯Ã¼·Î ¼Òº¯À¸·Î ¹è¼³µÈ´Ù.
3)±âŸ
-A. ÃÑ CLEARANCE: 39.3 L/hr (Á¤¸Æ Åõ¿©½Ã) (Fowles et al, 1992).
- ¹Ý°¨±â: 2.2 - 2.3 ½Ã°£
|
| Biotransformation |
Penciclovir¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Penciclovir¿¡ ´ëÇÑ Toxicity Á¤º¸ Symptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.
|
| Drug Interactions |
Penciclovir¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aluminium The multivalent agent decreases the effect of penicillamineAttapulgite The multivalent agent decreases the effect of penicillamineDigoxin The multivalent agent decreases the effect of penicillamineIron The multivalent agent decreases the effect of penicillamineKaolin The multivalent agent decreases the effect of penicillamine
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Penciclovir¿¡ ´ëÇÑ Description Á¤º¸ Penciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. [Wikipedia]
|
| Dosage Form |
Penciclovir¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream Topical
|
| Drug Category |
Penciclovir¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antiviral Agents
|
| Smiles String Canonical |
Penciclovir¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
|
| Smiles String Isomeric |
Penciclovir¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC1=NC(=O)C2=C(N1)N(CCC(CO)CO)C=N2
|
| InChI Identifier |
Penciclovir¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)/f/h13H,11H2
|
| Chemical IUPAC Name |
Penciclovir¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3H-purin-6-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-08-08
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
The database contains the following fields: The generic name of each chemical For module A10 (liver enzyme composite module): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the number of active and marginally active scores for each compound at the five individual endpoints (see research article for full description of method) Number of endpoints at which each compound is marginally active (M) Number of endpoints at which each compound is active (A) For modules A11 to A15 (alkaline phosphatase increased, SGOT increased, SGPT increased, LDH increased, and GGT increased, respectively): Overall activity category for each compound (A for active, M for marginally active, or I for inactive) based on the RI and ADR values (see the research article for full description of method) Number of ADR reports for each compound, given as <4 or ¡Ã4 Reporting Index value for each compound, except where no shipping units were available (NSU) Group 1 comprises of compounds for which ADR data were available for the first five years of marketing, so when no ADR reports were listed during this period the compounds were evaluated as inactive. Group 2 comprises of compounds for which a 'steady state' period of ADR data were available (1992-1996). In cases where no ADR reports were filed during this period, the compounds were scored as 'NA' (data not available) since they may have had one or more ADR reports during their first five years of marketing which should not be negated by a lack of ADR reports during the steady-state period. PENCICLOVIR[GGT Increase][Composite Activity](Score) I(Marginal) 0(Active) 0[Alkaline Phosphatase Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGOT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[SGPT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[LDH Increase](Activity Score) I(Number of Rpts) <4(Index value) 0[GGT Increase](Activity Score) I(Number of Rpts) <4(Index value) 0
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|